申请人:Kureha Chemical Industry Co., Ltd.
公开号:EP0686631A1
公开(公告)日:1995-12-13
A pyrimidine derivative of the formula (I):
wherein R¹ is a hydrogen atom, alkyl of 1 to 6 carbon atoms, haloalkyl of 1 to 6 carbon atoms, or -NHR¹¹ group;
R² is a hydrogen or halogen atom, alkyl of 1 to 6 carbon atoms, haloalkyl of 1 to 6 carbon atoms, -(CH₂)mC₆H₅, -NH₂, -NHR¹², -NH(CH₂)nC₆H₅, -NH(CH₂)pC₆H₄-OR¹³, -N(R¹⁴)(CH₂)qC₆H₅, -NHC(=O)R¹⁵, -NHC(=O)(CH₂)rC₆H₅, -NHC(=O)CH(C₆H₅)₂, -OR¹⁶, or -O(CH₂)sC₆H₅ group; R³ is -COOH, -COOR¹⁷, hydroxyl, -OR¹⁸, -NH₂, -N(R¹⁹)₂, -NHR²⁰, azole, or sulfonic acid group; R¹¹ is alkyl of 1 to 6 carbon atoms or haloalkyl of 1 to 6 carbon atoms; R¹², R¹³, R¹⁴, R¹⁵, R¹⁶, R¹⁷, R¹⁸, R¹⁹, and R²⁰ are independently alkyl of 1 to 6 carbon atoms; m is 0 or an integer of 1 to 6; n is 0 or an integer of 1 to 6; p is 0 or an integer of 1 to 6; q is 0 or an integer of 1 to 6; r is 0 or an integer of 1 to 6; and s is 0 or an integer of 1 to 6, or a salt thereof, and a pharmaceutical composition comprising said pyrimidine derivative or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier are disclosed.
式 (I) 的嘧啶衍生物:
其中 R¹ 是氢原子、1 至 6 个碳原子的烷基、1 至 6 个碳原子的卤代烷基或 -NHR¹¹ 基团;
R² 是氢原子或卤素原子、1 至 6 个碳原子的烷基、1 至 6 个碳原子的卤代烷基、-(CH₂)mC₆H₅、-NH₂、-NHR¹²、-NH(CH₂)nC₆H₅、-NH(CH₂)pC₆H₄-OR¹³, -N(R¹⁴)(CH₂)qC₆H₅, -NHC(=O)R¹⁵, -NHC(=O)(CH₂)rC₆H₅, -NHC(=O)CH(C₆H₅)₂, -OR¹⁶, 或 -O(CH₂)sC₆H₅ 组;R³ 是-COOH、-COOR¹⁷、羟基、-OR¹⁸、-NH₂、-N(R¹⁹)₂、-NHR²⁰、唑或磺酸基团;R¹¹是 1 至 6 个碳原子的烷基或 1 至 6 个碳原子的卤代烷基;R¹²、R¹³、R¹⁴、R¹⁵、R¹⁶、R¹⁷、R¹⁸、R¹⁹ 和 R²⁰ 独立地为 1-6 个碳原子的烷基;m 为 0 或 1-6 的整数;n 为 0 或 1-6 的整数;p 为 0 或 1-6 的整数;q 为 0 或 1-6 的整数;r为0或1至6的整数;s为0或1至6的整数,或其盐,以及包含所述嘧啶衍生物或其药学上可接受的盐和药学上可接受的载体的药物组合物。